Want to see IN:SYNGENE full AI Analyst Report?
SYNGENE Stock Chart & Stats
₹406.60
₹7.20(1.77%)
At close: 4:00 PM EDT
₹406.60
₹7.20(1.77%)
Day’s Range― - ―
52-Week Range₹375.50 - ₹684.00
Previous CloseN/A
Volume530.73K
Average Volume (3M)59.93K
Market Cap
₹162.78B
Enterprise Value₹169.48K
Total Cash (Recent Filing)₹12.19B
Total Debt (Recent Filing)₹4.73B
Price to Earnings (P/E)73.3
Beta0.76
Next Earnings
Oct 21, 2026EPS Estimate
0.67Next Dividend Ex-DateN/A
Dividend Yield0.31%
Share Statistics
EPS (TTM)5.50
Shares Outstanding403,669,160
10 Day Avg. Volume148,500
30 Day Avg. Volume59,929
Financial Highlights & Ratios
PEG Ratio-1.37
Price to Book (P/B)3.24
Price to Sales (P/S)4.20
P/FCF Ratio25.66
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)8.46
Revenue Forecast (FY)₹36.50B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetMaterial improvement in leverage and a large equity base provide durable financial resilience. Lower debt reduces solvency risk, supports funding for capex or capacity buildout, and gives flexibility to weather multi-quarter program slippage without forcing distress financing.
Integrated End-to-end CRDMO ModelOwning discovery-to-manufacturing capabilities creates sticky customer relationships and cross-sell opportunities. Capturing multiple stages of a program increases lifetime revenue per client and makes Syngene a strategic partner in secular outsourcing of pharma R&D.
Historically Solid Profitability And ROEConsistently healthy margins and mid-teens ROE over multiple years indicate durable operating leverage and disciplined cost structure. These fundamentals support ability to fund R&D, reinvest in capacity and sustain competitive service economics over cycles.
Bears Say
Sharp FY2026 Revenue And Earnings DropA large one-year revenue and profit contraction reduces visibility on backlog conversion and signals program delays or client spending cuts. If prolonged, it undermines operating leverage, hiring plans and the runway for converting discovery work into higher-margin development and manufacturing revenues.
Volatile Free Cash Flow And Weak ConversionMaterial volatility in free cash flow and subpar cash conversion versus net income create uncertainty for reinvestment, dividends and share repurchase programs. Persistent swings raise working-capital financing needs and can force trade-offs in capital allocation during recovery periods.
Negative Recent Growth TrendsMulti-period negative top-line and very large EPS decline reflect near-term structural headwinds in demand or program timing. Extended weak growth erodes bargaining power, raises customer concentration risks and limits the company's ability to scale fixed-cost investments profitably.
Syngene International Ltd. News
SYNGENE FAQ
What was Syngene International Ltd.’s price range in the past 12 months?
Syngene International Ltd. lowest stock price was ₹375.50 and its highest was ₹684.00 in the past 12 months.
What is Syngene International Ltd.’s market cap?
Syngene International Ltd.’s market cap is ₹162.78B.
When is Syngene International Ltd.’s upcoming earnings report date?
Syngene International Ltd.’s upcoming earnings report date is Oct 21, 2026 which is in 62 days.
How were Syngene International Ltd.’s earnings last quarter?
Syngene International Ltd. released its earnings results on Jul 29, 2026. The company reported ₹0 earnings per share for the quarter, missing the consensus estimate of ₹1.437 by -₹1.437.
Is Syngene International Ltd. overvalued?
According to Wall Street analysts Syngene International Ltd.’s price is currently Overvalued.
Does Syngene International Ltd. pay dividends?
Syngene International Ltd. pays a Annually dividend of ₹1.25 which represents an annual dividend yield of 0.31%. See more information on Syngene International Ltd. dividends here
What is Syngene International Ltd.’s EPS estimate?
Syngene International Ltd.’s EPS estimate is 0.67.
How many shares outstanding does Syngene International Ltd. have?
Syngene International Ltd. has 403,669,160 shares outstanding.
What happened to Syngene International Ltd.’s price movement after its last earnings report?
Syngene International Ltd. reported an EPS of ₹0 in its last earnings report, missing expectations of ₹1.437. Following the earnings report the stock price went up 1.075%.
Which hedge fund is a major shareholder of Syngene International Ltd.?
Currently, no hedge funds are holding shares in IN:SYNGENE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Syngene International Ltd.
Syngene International Limited, an India-based contract research and manufacturing organization (CRAMO), offers a wide array of drug discovery and development solutions to clients across India, the United States, and other international markets. The company's comprehensive service portfolio begins with discovery chemistry, encompassing medicinal and synthetic chemistry, library and peptide synthesis, biomolecule research, organic electronic materials, and specialized computational and analytical chemistry. In discovery biology, capabilities extend to recombinant DNA engineering, cell line development, hybridoma technology, sequencing, protein sciences, screening and assay biology, DMPK (Drug Metabolism and Pharmacokinetics), in vivo pharmacology, toxicology, and the development of biologicals. Syngene provides a full spectrum of toxicology services, from exploratory and in vitro studies to genetic, developmental, and reproductive toxicology, alongside acute, sub-chronic, and chronic toxicity assessments. Their development services include chemical, formulation, analytical, and clinical development, as well as commercial manufacturing. They also support crucial stages like lead generation, preclinical development, API (Active Pharmaceutical Ingredient) synthesis, and finished drug product development. For clinical trials, Syngene offers robust support, covering trial management, pharmacokinetic analysis/bioanalytical services, central laboratory operations, biometrics and clinical data management, regulatory affairs, medical monitoring, pharmacovigilance, and medical writing. Additionally, the company specializes in emerging drug modalities, such as peptides, oligonucleotide synthesis, antibody-drug conjugates (ADCs), PROTACs, and CAR T-cell therapies. Serving a diverse clientele that spans pharmaceutical, biotechnology, nutrition, animal health, consumer goods, and specialty chemical industries, Syngene has established key collaborations with entities like Bristol-Myers Squibb Co., Baxter Inc., and Amgen Inc. Incorporated in 1993 and headquartered in Bengaluru, India, Syngene International Limited operates as a subsidiary of Biocon Limited.
Technical Analysis
Biocon Limited
―
Concord Biotech Ltd.
―
Dishman Carbogen Amcis Ltd.
―
Panacea Biotec Limited
―
Anthem Biosciences Limited
―







